163 related articles for article (PubMed ID: 32172165)
21. Porous silicon-based sensing and delivery platforms for wound management applications.
Duan W; Zhao J; Gao Y; Xu K; Huang S; Zeng L; Shen JW; Zheng Y; Wu J
J Control Release; 2024 Jul; 371():530-554. PubMed ID: 38857787
[TBL] [Abstract][Full Text] [Related]
22. Mild thermotherapy and hyperbaric oxygen enhance sensitivity of TMZ/PSi nanoparticles via decreasing the stemness in glioma.
Zeng X; Wang Q; Tan X; Jia L; Li Y; Hu M; Zhang Z; Bai X; Zhu Y; Yang X
J Nanobiotechnology; 2019 Apr; 17(1):47. PubMed ID: 30935403
[TBL] [Abstract][Full Text] [Related]
23. Surface engineering of porous silicon microparticles for intravitreal sustained delivery of rapamycin.
Nieto A; Hou H; Moon SW; Sailor MJ; Freeman WR; Cheng L
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):1070-80. PubMed ID: 25613937
[TBL] [Abstract][Full Text] [Related]
24. Engineered Multifunctional Albumin-Decorated Porous Silicon Nanoparticles for FcRn Translocation of Insulin.
Martins JP; D'Auria R; Liu D; Fontana F; Ferreira MPA; Correia A; Kemell M; Moslova K; Mäkilä E; Salonen J; Casettari L; Hirvonen J; Sarmento B; Santos HA
Small; 2018 Jul; 14(27):e1800462. PubMed ID: 29855134
[TBL] [Abstract][Full Text] [Related]
25. Electrostatic interaction on loading of therapeutic peptide GLP-1 into porous silicon nanoparticles.
Kaasalainen M; Rytkönen J; Mäkilä E; Närvänen A; Salonen J
Langmuir; 2015 Feb; 31(5):1722-9. PubMed ID: 25604519
[TBL] [Abstract][Full Text] [Related]
26. Chitosan-modified porous silicon microparticles for enhanced permeability of insulin across intestinal cell monolayers.
Shrestha N; Shahbazi MA; Araújo F; Zhang H; Mäkilä EM; Kauppila J; Sarmento B; Salonen JJ; Hirvonen JT; Santos HA
Biomaterials; 2014 Aug; 35(25):7172-9. PubMed ID: 24844163
[TBL] [Abstract][Full Text] [Related]
27. Porous Silicon's Photoactivity in Water: Insights into Environmental Fate.
Moor KJ; Cates EL; Kim JH
Environ Sci Technol; 2016 Jan; 50(2):756-64. PubMed ID: 26741883
[TBL] [Abstract][Full Text] [Related]
28. Porous silicon-cell penetrating peptide hybrid nanocarrier for intracellular delivery of oligonucleotides.
Rytkönen J; Arukuusk P; Xu W; Kurrikoff K; Langel U; Lehto VP; Närvänen A
Mol Pharm; 2014 Feb; 11(2):382-90. PubMed ID: 24341621
[TBL] [Abstract][Full Text] [Related]
29. Hyperpolarized Porous Silicon Nanoparticles: Potential Theragnostic Material for
Seo H; Choi I; Whiting N; Hu J; Luu QS; Pudakalakatti S; McCowan C; Kim Y; Zacharias N; Lee S; Bhattacharya P; Lee Y
Chemphyschem; 2018 Sep; 19(17):2143-2147. PubMed ID: 29779258
[TBL] [Abstract][Full Text] [Related]
30. An Efficient, Versatile, and Safe Access to Supported Metallic Nanoparticles on Porous Silicon with Ionic Liquids.
Darwich W; Haumesser PH; Santini CC; Gaillard F
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27271608
[TBL] [Abstract][Full Text] [Related]
31. Development of porous silicon nanocarriers for parenteral peptide delivery.
Kovalainen M; Mönkäre J; Kaasalainen M; Riikonen J; Lehto VP; Salonen J; Herzig KH; Järvinen K
Mol Pharm; 2013 Jan; 10(1):353-9. PubMed ID: 23186283
[TBL] [Abstract][Full Text] [Related]
32. Multifunctional porous silicon for therapeutic drug delivery and imaging.
Santos HA; Bimbo LM; Lehto VP; Airaksinen AJ; Salonen J; Hirvonen J
Curr Drug Discov Technol; 2011 Sep; 8(3):228-49. PubMed ID: 21291407
[TBL] [Abstract][Full Text] [Related]
33. Immobilisation and synthesis of DNA on Si(111), nanocrystalline porous silicon and silicon nanoparticles.
Lie LH; Patole SN; Pike AR; Ryder LC; Connolly BA; Ward AD; Tuite EM; Houlton A; Horrocks BR
Faraday Discuss; 2004; 125():235-49; discussion 293-309. PubMed ID: 14750674
[TBL] [Abstract][Full Text] [Related]
34. Effect of isotonic solutions and peptide adsorption on zeta potential of porous silicon nanoparticle drug delivery formulations.
Kaasalainen M; Mäkilä E; Riikonen J; Kovalainen M; Järvinen K; Herzig KH; Lehto VP; Salonen J
Int J Pharm; 2012 Jul; 431(1-2):230-6. PubMed ID: 22569227
[TBL] [Abstract][Full Text] [Related]
35. The impact of porous silicon nanoparticles on human cytochrome P450 metabolism in human liver microsomes in vitro.
Ollikainen E; Liu D; Kallio A; Mäkilä E; Zhang H; Salonen J; Santos HA; Sikanen TM
Eur J Pharm Sci; 2017 Jun; 104():124-132. PubMed ID: 28366651
[TBL] [Abstract][Full Text] [Related]
36. Investigation of silicon nanoparticles produced by centrifuge chemical vapor deposition for applications in therapy and diagnostics.
Lumen D; Wang S; Mäkilä E; Imlimthan S; Sarparanta M; Correia A; Westerveld Haug C; Hirvonen J; Santos HA; Airaksinen AJ; Filtvedt W; Salonen J
Eur J Pharm Biopharm; 2021 Jan; 158():254-265. PubMed ID: 33279602
[TBL] [Abstract][Full Text] [Related]
37. A novel approach for osteocalcin detection by competitive ELISA using porous silicon as a substrate.
Rahimi F; Mohammadnejad Arough J; Yaghoobi M; Davoodi H; Sepehri F; Amirabadizadeh M
Biotechnol Appl Biochem; 2017 Nov; 64(6):871-878. PubMed ID: 27775855
[TBL] [Abstract][Full Text] [Related]
38. pH-Operated mechanized porous silicon nanoparticles.
Xue M; Zhong X; Shaposhnik Z; Qu Y; Tamanoi F; Duan X; Zink JI
J Am Chem Soc; 2011 Jun; 133(23):8798-801. PubMed ID: 21595466
[TBL] [Abstract][Full Text] [Related]
39. Porous silicon for drug delivery applications and theranostics: recent advances, critical review and perspectives.
Kumeria T; McInnes SJP; Maher S; Santos A
Expert Opin Drug Deliv; 2017 Dec; 14(12):1407-1422. PubMed ID: 28398108
[TBL] [Abstract][Full Text] [Related]
40. Controlling and Predicting the Dissolution Kinetics of Thermally Oxidised Mesoporous Silicon Particles: Towards Improved Drug Delivery.
Wang F; Barnes TJ; Prestidge CA
Pharmaceutics; 2019 Nov; 11(12):. PubMed ID: 31795166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
